<DOC>
	<DOCNO>NCT01425450</DOCNO>
	<brief_summary>The study aim : - study safety drug ( HF1020 ) healthy male adult - study well study drug ( HF1020 ) tolerate healthy male adult - find maximum dose tolerate healthy male adult</brief_summary>
	<brief_title>Safety Study Four Doses Study Drug , HF1020 Healthy Volunteers</brief_title>
	<detailed_description>This single-centre , randomised , double-blind , placebo-controlled , ascend dose study . Male subject randomise give total 32 evaluable subject . Subjects sequentially enrol 4 cohort ascend dose . Subjects Cohort 1 randomise receive 0.5 milligram ( mg ) HF1020 placebo ( ratio 3:1 ) . When least 8 subject within cohort complete Day 2 procedure ( i.e . Day 1 + 24 hour ) ongoing subject complete final Day 15 visit , Safety Review Committee ( SRC ) meet , review safety data prior dose escalation next cohort . Subjects Cohort 2 randomise receive 2.5 mg HF1020 placebo . Subjects Cohort 3 randomise receive 10mg HF1020 placebo . Subjects Cohort 4 randomise receive 25mg HF1020 placebo .</detailed_description>
	<criteria>Subject male Subject age 18 65 year inclusive Subject able willing provide sign informed consent Subject 's body mass index ( BMI ) 18 32 kg/m2 inclusive Nonsmokers ex smoker ( great 1 year ) less 5 pack/year history Subject 's medical history consider normal opinion Investigator , clinically significant abnormality . No history asthma concurrent clinically significant illness concomitant medication use ( exception paracetamol NonSteroidal antiinflammatory drug ( NSAIDs ) take need study ) . Subject consider good health opinion Investigator . Normal/clinically acceptable vital sign ( blood pressure ( systolic blood pressure 100140mmHg , diastolic blood pressure 6090mmHg ; heart rate 40100bpm ) , physical examination Electrocardiogram ( ECG ) , determine Investigator . Subject 's screening pre dose clinical laboratory finding within normal range outside normal range deem clinically significant opinion Investigator . Lymphocyte subset must within normal limit QTcB le equal 450 msec screen predose Subject must willing abstain alcohol 48 hour prior admission unit ( include screen visit ) discharge CRU . Subjects must willing abstain grapefruit , grapefruitcontaining product , cranberry juice , Seville oranges , marmalade pomelos 7 day prior screen participation study . Subjects must willing abstain exercise strenuous walking , 48 hour prior study visit Subjects must willing avoid sperm donation abstain actively plan pregnancy three month end study . Male subject female partner child bear potential must use 2 different form highly effective contraception throughout study ; establish use oral , injected/implanted hormonal contraception ; placement intrauterine device intrauterine system ; use barrier method contraception ( condom occlusive cap use spermicide ) ; male sterilisation ( postvasectomy documentation absence sperm ejaculate must provide ) . Female partner pregnant breastfeeding . Subjects require continue use contraceptive method 3 month final study visit . In addition , sexually active subject must use condom irrespective sex partner childbearing potential partner even vasectomise , study three month final study visit . Forced Expiratory Volume one second ( FEV1 ) Forced Vital Capacity ( FVC ) great equal 80 % predict normal value Screening Visit FEV1/FVC ratio great equal 0.70 Screening Visit Subject must willing remain Clinical Research Unit ( CRU ) minimum two night . Subjects must able communicate well Investigator , understand comply requirement restriction study , understand sign write informed consent Subject clinically significant illness four week screen runin period Subject significant history drug/solvent abuse ( within two year prior Day 1 ) , positive drug abuse test screen prior randomisation Subject history alcohol abuse currently drink excess 28 unit per week , positive breath alcohol test Screening Visit prior randomisation Subject , opinion Investigator , suitable participate study Subject participate clinical study receipt investigational drug within 3 month prior Day 1 Subject positive result human immunodeficiency virus ( HIV ) Hepatitis B Hepatitis C screen Subject serious adverse reaction significant hypersensitivity drug Subject donate 500 ml blood , experience blood loss 500 ml , within 3 month prior Day 1 ; donate plasma within 7 day prior Day 1 Any condition might interfere absorption , distribution , metabolism , and/or excretion drug Considering schedule undergo surgical procedure duration study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>